Piperacillin And Tazobactam

Introduction Overview

Generic Name

piperacillin and tazobactam

Brand Name

Zosyn

Dosage Form

Intravenous infusion (IV)

Drug Class

Penicillins / beta-lactamase inhibitors

Pharmacokinetics

Absorption:
Zosyn is administered intravenously, bypassing the gastrointestinal tract and thus exhibiting complete bioavailability. The intravenous administration ensures immediate and complete systemic availability of both piperacillin and tazobactam, crucial for rapid therapeutic effects in severe infections. As such, no oral absorption parameters apply. The rapid delivery into systemic circulation allows for optimal peak plasma concentrations essential for effective bactericidal activity.

Distribution:
After intravenous administration, piperacillin and tazobactam distribute widely into body tissues and fluids, including the lungs, skin, soft tissues, abdomen, and uterine tissues. The volume of distribution of piperacillin approximates 0.2 L/kg, indicative of distribution primarily to extracellular fluids. Both agents penetrate inflamed tissues well but have limited penetration through the blood-brain barrier in the absence of inflammation, which is clinically relevant in central nervous system infections. Protein binding is approximately 30% for piperacillin and is negligible for tazobactam, facilitating extensive tissue distribution.

Metabolism:
Piperacillin undergoes minimal hepatic metabolism; it is predominantly excreted unchanged in the urine. Tazobactam is partially metabolized by the liver, with about 30% undergoing biotransformation into inactive metabolites. The limited metabolism of these drugs reduces concerns about active hepatic metabolites, but liver dysfunction may alter clearance of tazobactam metabolites, though no dosage adjustment is typically necessary solely for mild to moderate hepatic impairment.

Elimination:
Both piperacillin and tazobactam are primarily eliminated renally via glomerular filtration and tubular secretion. The elimination half-life is approximately 1 hour in patients with normal renal function. Renal impairment significantly prolongs elimination half-life and reduces clearance, necessitating dosage adjustments based on creatinine clearance to avoid accumulation and toxicity. Both drugs are excreted primarily as unchanged active compounds, contributing to their antibacterial activity in the urinary tract and systemic circulation. Hemodialysis can remove piperacillin and tazobactam effectively, and supplemental dosing post-dialysis may be required.

Dosage Forms

Available Dosage Forms:
- Intravenous (IV) infusion:
* Vials containing piperacillin and tazobactam combinations; typical strengths include 2.25 g (piperacillin 2 g and tazobactam 0.25 g), 3.375 g (piperacillin 3 g and tazobactam 0.375 g), 4.5 g (piperacillin 4 g and tazobactam 0.5 g).
* Prepared for IV infusion over a specified time period, typically 30 to 60 minutes.

Dosages for Adults and Adolescents:
- For moderate to severe infections, the usual adult dose in patients with normal renal function is 3.375 g every 6 hours or 4.5 g every 6 to 8 hours, administered intravenously.
- For hospital-acquired pneumonia or complicated infections, dosing may be intensified with 4.5 g every 6 hours.
- The duration of therapy depends on infection severity and clinical response and commonly ranges from 7 to 14 days but may be extended based on infection site and response.

Specific Patient Populations:
- Renal impairment requires dose adjustment based on creatinine clearance; dosing intervals are extended or doses reduced to prevent accumulation.
- No specific dosage adjustments generally required for mild to moderate hepatic impairment, but monitoring is recommended.
- Use in pediatric populations is off-label; dosage regimens must be carefully tailored.
- Pregnant and breastfeeding patients should only receive Zosyn if clearly needed, with monitoring.

Storage and Handling:
- Reconstituted single-dose vials must be used immediately or discarded within 24 hours if stored at room temperature or 48 hours if refrigerated.
- Mixed IV solutions can be stored refrigerated up to 7 days.
- Solutions should not be frozen.
- Proper disposal protocols for needles, syringes, and IV tubing must be followed to prevent contamination and injury.

Mechanism Of Action

Zosyn combines two active components: piperacillin, an extended-spectrum penicillin antibiotic, and tazobactam, a beta-lactamase inhibitor. Piperacillin’s bactericidal action stems from its ability to inhibit bacterial cell wall synthesis. It achieves this by binding to penicillin-binding proteins (PBPs) located inside the bacterial cell wall. PBPs are enzymes critical for the cross-linking of peptidoglycan strands that provide cell wall rigidity and structural integrity. Inhibition of these PBPs disrupts cell wall synthesis, leading to cell lysis and death.

Tazobactam is structurally related to beta-lactam antibiotics and acts as a suicide inhibitor of beta-lactamase enzymes produced by many resistant bacteria. These enzymes degrade the beta-lactam ring of penicillin antibiotics, rendering them ineffective. By irreversibly binding to beta-lactamase enzymes, tazobactam protects piperacillin from enzymatic degradation, thereby extending its spectrum of antibacterial activity especially against beta-lactamase-producing strains.

Clinically, this dual mechanism allows Zosyn to be effective against a broad range of gram-positive, gram-negative, and anaerobic bacteria, including challenging nosocomial pathogens. Unlike some penicillins, the addition of tazobactam enables activity against bacteria producing common beta-lactamases, which would otherwise confer resistance. This makes Zosyn an important agent in treating polymicrobial infections and infections caused by multi-resistant strains.

Furthermore, compared to other beta-lactam/beta-lactamase inhibitor combinations, Zosyn exhibits enhanced efficacy against Pseudomonas aeruginosa due to piperacillin’s intrinsic activity and tazobactam's inhibitor properties. Research studies and clinical trials have demonstrated that this combination provides improved clinical outcomes in complicated intra-abdominal infections, skin and soft tissue infections, and hospital-acquired pneumonia when compared to single-agent therapies.

Pharmacological Actions

Bactericidal activity through inhibition of bacterial cell wall synthesis by piperacillin.
Beta-lactamase inhibition by tazobactam that protects piperacillin from degradation by beta-lactamase enzymes.
Broad-spectrum antimicrobial activity against aerobic gram-positive and gram-negative bacteria, and anaerobes.
Effective against many beta-lactamase-producing pathogens, expanding coverage to resistant organisms.
Synergistic action enhances treatment of polymicrobial infections.
Activity against Pseudomonas aeruginosa, a common hospital-acquired pathogen.
Rapid bactericidal effect suitable for severe and complicated infections.
Minimal metabolism leading to predictable pharmacokinetics and dosing.
Renal excretion of active drugs facilitates activity in urinary tract infections.
Low protein binding of tazobactam aiding widespread tissue penetration.
Immunomodulatory effects are minimal, reducing risk of altered host defenses.
Demonstrated efficacy in treatment of skin, soft tissue, abdominal, and respiratory infections.
Reduced risk of resistance development when used in appropriate combinations and durations.
Compatibility with other antibiotics allows for combination therapy in complex infections.
Well-characterized safety profile facilitates use in critically ill patients.

Therapeutic Or Clinical Uses

Treatment of moderate to severe bacterial infections caused by susceptible organisms.
Complicated intra-abdominal infections including peritonitis.
Skin and soft tissue infections including diabetic foot infections.
Hospital-acquired and ventilator-associated pneumonia.
Severe uterine infections such as endometritis and pelvic inflammatory disease.
Bacteremia and septicemia caused by susceptible bacteria.
Empiric therapy for febrile neutropenia due to broad-spectrum coverage.
Treatment of urinary tract infections caused by beta-lactamase producing bacteria.
Treatment of bone and joint infections where beta-lactamase producing organisms are involved.
Combination therapy for infections where polymicrobial flora including anaerobes are suspected.
Postoperative infections prevention where gram-negative and anaerobic coverage is needed.
Use in cystic fibrosis patients for pulmonary exacerbations caused by Pseudomonas species.
Management of healthcare-associated infections requiring potent beta-lactam/beta-lactamase inhibitor therapy.
Rescue therapy in infections resistant to single beta-lactam agents due to beta-lactamase production.
Treatment of burn wound infections involving multidrug resistant organisms.

Side Or Adverse Effects

Hypersensitivity reactions including rash, urticaria, and anaphylaxis especially in patients with penicillin allergy.
Gastrointestinal disturbances such as diarrhea, nausea, and constipation.
Potential for Clostridioides difficile-associated diarrhea and colitis, including severe forms.
Hematologic effects: transient leukopenia, neutropenia, thrombocytopenia, and eosinophilia.
Electrolyte abnormalities including hypokalemia manifesting as muscle cramps, weakness, and arrhythmias.
Injection site reactions such as pain, phlebitis, and inflammation.
Headache and insomnia reported as neurological side effects.
Confusion and seizures rarely reported, more frequent in patients with renal impairment or CNS disorders.
Elevated liver enzymes indicating transient hepatotoxicity in some cases.
Serum creatinine elevations indicating possible renal function changes.
Severe skin reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis (rare).
Superinfections or secondary infections with prolonged therapy.
Bleeding tendencies especially in patients with concomitant anticoagulant therapy or coagulopathies.
Potential development of antibiotic resistance with inappropriate use.
Rare reports of interstitial nephritis and other immune-mediated reactions.

Precautions

Assess for allergy to penicillins, cephalosporins, or beta-lactam agents before initiation.
Use with caution in patients with a history of hypersensitivity reactions to antibiotics.
Monitor renal function closely, especially in patients with pre-existing kidney disease.
Adjust dosing in renal impairment to avoid drug accumulation and toxicity.
Electrolyte monitoring is advised to detect and correct hypokalemia.
Avoid premature discontinuation to prevent emergence of resistant bacterial strains.
Use cautiously in patients with bleeding disorders or receiving anticoagulant therapy due to increased bleeding risk.
Close monitoring for signs of superinfection or Clostridioides difficile-associated diarrhea during and after treatment.
Patients with cystic fibrosis may require careful monitoring due to altered pharmacokinetics.
Pregnancy and breastfeeding use only if clearly needed and under medical supervision.
Proper preparation and handling to maintain sterility and drug stability.
Ensure patient education on use, storage, and disposal of IV equipment and drug preparations.
Avoid concurrent use with nephrotoxic drugs where possible to reduce risk of renal damage.
Educate patients to report symptoms of hypersensitivity or severe skin reactions immediately.
Regular complete blood counts recommended during prolonged therapy to detect hematologic side effects.

Warnings

Contraindicated in patients with known hypersensitivity to piperacillin, tazobactam, penicillins, or cephalosporins.
Risk of serious allergic reactions including anaphylaxis, which may be life-threatening.
Potential for bleeding abnormalities, especially in patients with renal impairment or on anticoagulants.
Risk of Clostridioides difficile-associated diarrhea and pseudomembranous colitis, which can be severe.
Use for full prescribed duration even if symptoms improve to prevent resistant organisms.
Not effective against viral infections; inappropriate use increases resistance risk.
Possible severe skin reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis.
May cause electrolyte disturbances, particularly hypokalemia with associated cardiac risks.
Accumulate in renal impairment leading to increased adverse events if dose not adjusted.
Interactions with other medications that affect blood clotting require careful management.
Requires sterile handling and administration to prevent infection or contamination.
Careful patient monitoring recommended in high-risk populations including elderly or immunocompromised.
Use caution or avoid use if history of seizures or CNS disorders as drug may lower seizure threshold.
May interfere with certain laboratory tests, necessitating physician awareness.
Proper disposal of needles and infusion sets needed to prevent accidental injury or infection.

Contraindication

Known hypersensitivity to piperacillin, tazobactam, or any component of the formulation.
History of severe allergic reactions to penicillin or other beta-lactam antibiotics.
Allergy to cephalosporins due to potential cross-reactivity.
Patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior use of piperacillin/tazobactam.
Use contraindicated in neonates due to benzyl alcohol content in some formulations (consult specific product labeling).
Past severe cutaneous adverse reactions to beta-lactam antibiotics.
Known hypersensitivity to clavulanic acid or other beta-lactamase inhibitors (cross-reactivity caution).
Patients with history of antibiotic-associated colitis should avoid use unless benefits outweigh risks.
Known hypersensitivity to any beta-lactam antibiotic class including carbapenems may warrant avoidance.
Patients with bleeding disorders may require alternative therapies due to bleeding risk.
Use of Zosyn in combination with methotrexate contraindicated without adequate monitoring due to increased toxicity risk.
Concurrent use with certain anticoagulants without appropriate monitoring is contraindicated.
Patients with galactose intolerance or glucose-galactose malabsorption should avoid some formulations with added excipients.
Hypersensitivity to any preservatives or stabilizers present in specific Zosyn formulations.
Incompatible with certain IV drugs; contraindicated for simultaneous administration without proper separation.
Patients with severe hepatic impairment may require alternative antibiotic choices.

Drug Interactions

Increased risk of bleeding when co-administered with anticoagulants such as warfarin, heparin, and direct thrombin inhibitors.
Potential additive nephrotoxicity when used concomitantly with other nephrotoxic agents like aminoglycosides or vancomycin.
Possible reduction in efficacy of oral contraceptives when combined with broad-spectrum antibiotics, including Zosyn.
Concomitant use with methotrexate can increase methotrexate toxicity due to reduced renal clearance.
May interfere with certain laboratory tests including Coombs test, possibly causing false-positive results.
Probenecid may decrease renal tubular secretion of piperacillin, increasing serum levels and toxicity risk.
Loop diuretics combined with Zosyn may enhance risk of hypokalemia requiring electrolyte monitoring.
Concurrent administration with valproic acid may reduce valproic acid plasma concentrations, increasing seizure risk.
Concomitant use with live bacterial vaccines may diminish vaccine efficacy.
Use with neuromuscular blocking agents may potentiate neuromuscular blockade, necessitating close monitoring.
Potential interactions with cyclosporine or tacrolimus may increase nephrotoxicity risk.
Co-administration with oral anticoagulants requires monitoring of coagulation parameters due to altered effects.
Combination with other beta-lactam antibiotics may increase risk of antagonistic effects.
Simultaneous use with certain antiepileptic drugs may require dose adjustments and therapeutic drug monitoring.
Herbal supplements and vitamins should be reviewed with healthcare provider due to unknown interaction potential.

Preparations Of The Drug

Zosyn is supplied as a sterile powder for intravenous infusion, contained in single-dose vials.
Common vial strengths include 2.25 g (piperacillin 2 g and tazobactam 0.25 g), 3.375 g, and 4.5 g combinations.
Powder requires reconstitution with sterile water or compatible diluent prior to administration.
Reconstituted solutions should be further diluted in IV bags with compatible fluids such as normal saline or dextrose solutions.
Storage conditions vary by preparation: reconstituted syringes stable for 48 hours refrigerated, IV bags stable for up to 7 days refrigerated.
Do not freeze reconstituted or mixed solutions to preserve stability and potency.
Prefilled syringes and ready-to-use infusions are available to facilitate administration in clinical settings.
Packaging designed to maintain sterility and prevent contamination during storage and handling.
Instructions for use include aseptic technique, appropriate dilution, and infusion rates to optimize safety and efficacy.
Disposal of unused drug and paraphernalia must comply with local regulations for hazardous medical waste.
Different formulations may contain excipients and preservatives requiring attention for allergic or intolerant patients.
Compatibility charts provide guidance on co-administration with other IV drugs to prevent precipitation or inactivation.
Labeling includes detailed reconstitution, storage, administration, and disposal instructions for healthcare providers.
Specialized packaging such as Galaxy containers approved by FDA for certain formulations to maintain stability.
Unit-dose packaging minimizes medication errors and supports accurate dosing in hospital settings.